23 May 2013
Keywords: boehringer, ingelheim, nascacell, enter, alliance, germany, say
Article | 21 February 2005
Germany's Boehringer Ingelheim and NascaCell say they have signed a deal on aptamer-based target validation and drug discovery. Under the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 February 2005
© 2013 thepharmaletter.com